About Toolstation Toolstation outsources its logistics operations in the Netherlands for the first time EINDHOVEN, The Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- GXO Logistics, Inc., the world's largest pure-play contract logistics provider, today announced a new partnership in the Netherlands with Toolstation, a leading supplier of building supplies and tools for professionals and serious DIY customers, and one of the fastest growing businesses in Europe. The agreement marks Toolstation's first outsourc ...

Core Viewpoint - Regulus Resources Inc. is advancing its Phase Two metallurgical test program with Nuton LLC, focusing on bio-leaching technologies for the AntaKori copper-gold project, while also progressing on an integrated resource estimate with Compañía Minera Coimolache S.A. for the Integrated Sulphide Project [1][4]. Nuton Phase Two Program - The Phase One program confirmed that AntaKori material is suitable for Nuton's proprietary sulphide bio-leaching technology [2]. - The Phase Two program is evaluating various conditions for optimal leaching of enargite-rich high-sulphidation mineralization, with the highest copper extraction achieved so far being 88.3% [3]. - Additional columns have been initiated to further refine the optimal conditions for leaching [3]. Integrated Sulphide Project - Regulus and Coimolache are collaboratively developing an integrated geological model for the Integrated Sulphide Project, which is a prerequisite for the resource estimate [4]. - SRK Peru has been contracted to complete the resource estimate, expected to be finalized by mid-year [4]. Company Insights - The CEO of Regulus expressed optimism regarding the results from the Phase Two program, highlighting the potential of Nuton's bio-leaching technology for both high-sulphidation and porphyry mineralization [5]. - The AntaKori project currently hosts indicated mineral resources of 250 million tonnes at a grade of 0.48% Cu, 0.29 g/t Au, and 7.5 g/t Ag, and inferred mineral resources of 267 million tonnes at a grade of 0.41% Cu, 0.26 g/t Au, and 7.8 g/t Ag [7].

Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company utilizes its proprietary PLEX technology for controlled, prolonged-release of drugs, enabling precise delivery over several days to months [4] - PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing abdominal colorectal surgical site infections [4] Upcoming Events - PolyPid will participate in the Lytham Partners Spring 2025 Investor Conference, with a webcast presentation scheduled for May 29, 2025, at 10:15 a.m. ET [2] - The webcast will be accessible via the conference homepage and will be available for replay after the event [2] - Management will also engage in virtual one-on-one meetings with investors during the conference [3]

Core Insights - Plug Power Inc. has successfully operationalized its GenEco electrolyzer systems at The Green Box in the Netherlands, showcasing its capabilities to European customers [1][3] - The GenEco platform is designed for flexible deployment in various industrial applications, including refining, sustainable aviation fuel, and green ammonia production [2] - The establishment of a live demonstration site is a strategic move to bolster confidence in Plug's technology and facilitate ongoing commercial discussions in Europe [3] Company Developments - The Green Box serves as a hub for innovation and customer showcase, enhancing Plug's presence in the European market [5] - Plug Power's electrolyzer opportunity pipeline exceeds $21 billion for 2025 and 2026, supported by initiatives like the EU Green Deal and RePowerEU [5] - The site features advanced energy infrastructure, including a 6 MW public grid connection and a 10 kV network, with over 18,000 solar panels meeting most of its electricity needs [4] Technology and Operations - The 5 MW GenEco system has demonstrated successful hydrogen production, primarily powered by on-site solar energy, highlighting economic advantages [3] - Plug Power has deployed over 72,000 fuel cell systems and 275 fueling stations globally, leading in hydrogen production [7] - The company operates hydrogen plants in Georgia, Tennessee, and Louisiana, producing 40 tons of hydrogen per day [7]

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Currency Exchange International Corp. (TSX: CXI; OTCQX: CURN), which provides comprehensive foreign exchange technology and processing services, has qualified to trade on the OTCQX® Best Market. Currency Exchange International Corp upgraded to OTCQX from the Pink® market. Currency Exchange International Corp. begins trading today ...

Core Viewpoint - NANO Nuclear Energy Inc. has launched a significant irradiation testing program in collaboration with MIT to study the behavior of nitrate molten salts under radiation, which is crucial for the development of next-generation nuclear reactors [1][3][5] Group 1: Collaboration and Research Focus - The two-year collaboration with MIT will investigate the thermal and radiolytic behavior of nitrate molten salts for advanced nuclear energy systems [1][3] - The research is funded by NANO Nuclear with over $500,000 and will be supervised by Prof. Koroush Shirvan, a leading expert in nuclear systems engineering [2][3] - The study aims to fill the knowledge gap regarding the performance of molten salts under ionizing radiation, which is essential for nuclear environments [3][4] Group 2: Research Methodology and Expected Outcomes - MIT researchers will utilize advanced diagnostics to measure off-gassing behavior, thermal degradation, and long-term material stability of the salts [4][5] - The results will directly inform the design of microreactors that use molten salts for heat transfer and energy storage, enhancing safety and performance models [4][5] - The project is expected to conclude in 2027, with quarterly updates and final data delivery coordinated between MIT and NANO Nuclear [6] Group 3: Company Overview and Future Directions - NANO Nuclear is focused on becoming a diversified and vertically integrated company across five business lines, including microreactor technologies and nuclear fuel fabrication [7] - The company is developing several advanced reactor products, including the KRONOS MMR Energy System and the portable LOKI MMR [8][9] - NANO Nuclear's subsidiaries are also exploring commercial applications of micronuclear reactor technology in space and developing a domestic HALEU fuel fabrication pipeline [10][11][12]

Partnership combines Mobilicom's groundbreaking OS3 cybersecurity software with ARK's made-in-the- USA, BLUE UAS listed, NDAA compliant, NVIDIA AI-driven hardware ARK joins Mobilicom's booth at XPONENTIAL 2025, a gathering of global leaders and end users in the uncrewed systems and robotics industry, to feature the companies' upcoming joint products First product expected to launch H2 2025 Both companies have products on the Blue UAS Framework, which provides a prestigious shortlist of rigorously vetted pro ...

Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [1][2] - The management team of I-Mab will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, discussing clinical progress on its lead program, givastomig [1][2] - New data on givastomig has been accepted for a Mini Oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain [2] Company Information - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company is publicly traded on NASDAQ under the ticker IMAB [1][2] - For more information, I-Mab's website and social media channels are available [2]

Core Insights - Helius Medical Technologies, Inc. will present the final results of the PoNSTEP study, which confirms the efficacy of the Portable Neuromodulation Stimulator (PoNS) device for improving gait in individuals with multiple sclerosis (MS) [1][2] - The study highlights a statistically significant relationship between adherence to PoNS therapy and improvement in gait, indicating that consistent use leads to sustained benefits [3][4] Study Overview - The PoNSTEP study was a three-phase, real-world therapeutic experience designed to evaluate the impact of adherence on gait deficits and long-term outcomes in MS patients [3][8] - Participants underwent two weeks of supervised therapy, followed by 12 weeks of combined clinic and at-home use, concluding with a six-month follow-up to assess the durability of improvements [3][9] Key Findings - Stronger adherence to PoNS therapy resulted in better therapeutic outcomes, with highly adherent participants achieving over 6 points improvement in their Dynamic Gait Index (DGI) scores during the first 14 weeks [4][5] - More than 95% of participants maintained their level of improvement six months post-treatment, demonstrating the durability of the therapy's effects [5][7] Clinical Implications - The study provides evidence of the effectiveness of neuromodulation and neuroplasticity in rehabilitating gait deficits in MS patients, marking a significant advancement in treatment options for this population [7][10] - PoNS therapy is now accessible through insurance via the U.S. Department of Veterans Affairs and Department of Defense, with some commercial healthcare providers beginning to reimburse the device [7][12] About PoNS Device - The Portable Neuromodulation Stimulator (PoNS) is a non-implantable device that delivers neurostimulation through a mouthpiece, used in conjunction with physical rehabilitation exercises to improve balance and gait in MS patients [12][14] - The device is indicated for short-term treatment of gait deficits due to mild-to-moderate MS symptoms and is prescribed for patients aged 22 and older [12][13]

DETROIT, May 20, 2025 (GLOBE NEWSWIRE) -- DT Midstream, Inc. (NYSE: DTM) announced that it has achieved an investment grade rating with two agencies: With investment grade ratings from these two credit agencies, DTM expects an improvement in liquidity and reduced interest expense. "Achievement of an investment grade credit rating was a strategic goal we had since we became a standalone public company," said David Slater, President and CEO. "The ratings upgrades are a recognition of the strength of our balan ...